Article
Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.
Cancer cell - 14 May 2018
Mackay Alan, Burford Anna, Molinari Valeria, Jones David T W, Izquierdo Elisa, Brouwer-Visser Jurriaan, Giangaspero Felice, Haberler Christine, Pietsch Torsten, Jacques Thomas S, Figarella-Branger Dominique, Rodriguez Daniel, Morgan Paul S, Raman Pichai, Waanders Angela J, Resnick Adam C, Massimino Maura, Garrè Maria Luisa, Smith Helen, Capper David, Pfister Stefan M, Würdinger Thomas, Tam Rachel, Garcia Josep, Thakur Meghna Das, Vassal Gilles, Grill Jacques, Jaspan Tim, Varlet Pascale, Jones Chris
Abstract excerpt
The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between the ages of 3 and 18 years. We carried out comprehensive molecular analysis integrated with pathology, radiology, and immune profiling. In post-hoc subgroup analysis, hypermutator tumors...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
